Your browser doesn't support javascript.
loading
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada.
Kim, Yong-Jin; Oremus, Mark; Chen, Helen H; McFarlane, Thomas; Fearon, Danielle; Horton, Susan.
Afiliação
  • Kim YJ; School of Public Health and Health Systems, University of Waterloo, Lyle Hallman North Building-2714, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada. y238kim@uwaterloo.ca.
  • Oremus M; School of Public Health and Health Systems, University of Waterloo, Lyle Hallman North Building-2714, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada.
  • Chen HH; School of Public Health and Health Systems, University of Waterloo, Lyle Hallman North Building-2714, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada.
  • McFarlane T; School of Pharmacy, University of Waterloo, Kitchener, ON, Canada.
  • Fearon D; School of Public Health and Health Systems, University of Waterloo, Lyle Hallman North Building-2714, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada.
  • Horton S; School of Public Health and Health Systems, University of Waterloo, Lyle Hallman North Building-2714, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada.
Pharmacoeconomics ; 39(5): 537-548, 2021 05.
Article em En | MEDLINE | ID: mdl-33786799
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Idioma: En Ano de publicação: 2021 Tipo de documento: Article